FDA to decide on Sanofi/Regeneron’s Dupixent for COPD in June
Sanofi and Regeneron’s Dupixent has received priority review by the US FDA, with a target action date of 27 June.
Sanofi and Regeneron’s Dupixent has received priority review by the US FDA, with a target action date of 27 June.
What's Your Reaction?
